VerbatimParliament, as it happens

Elacestrant

Asked by Jim ShannonDemocratic Unionist PartyDepartment of Health and Social CareTabled Answered 4 February 2025UIN 27188

The question

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of Elacestrant.

Answered by Karin Smyth

The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS based on an assessment of their costs and benefits. The NHS is legally required to fund medicines recommended by the NICE, and cancer medicines are eligible for funding from the Cancer Drugs Fund from the point of positive NICE draft guidance.

The NICE recommended elacestrant as an option for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in final draft guidance on 19 December 2024, and it is now funded for eligible patients in England through the Cancer Drugs Fund. Final guidance is due to publish on 5 February 2025.

Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →

Open this question in Verbatim →

Every written question, searchable

155,000 questions tabled since the election, with the answer each department gave — and the ones still unanswered, with the clock running. Free to search.

Search written questions →Read on Verbatim